EGFR and non-small cell lung carcinoma: Additionally, ALDH1A3 expression was reported to be enriched in EGFR-mutated non-small cell lung carcinoma cells resistant to the EGFR tyrosine kinase inhibitor erlotinib [80], suggesting that ALDH1A3-expressing cancer cells are resistant to other treatments beyond chemotherapy.